Search Results
Your search for The matches 34697 pages
Showing 15501 - 155502019 ASCO: Nearly One-Quarter of Participants in the Pediatric MATCH Trial Have an Actionable Molecular Alteration
A study investigating the frequency of targetable molecular alterations in pediatric cancer among patients enrolled in the National Cancer Institute–Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) trial has found that about one-quarter of patients with...
2019 ASCO: Entrectinib in Children and Adolescents With Recurrent or Refractory Solid or Central Nervous System Tumors
A phase I/IB study evaluating the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors, including central nervous system (CNS) tumors, has found that the agent produced responses in children with tumors harboring target aberrations...
2019 ASCO: Low-Fat Diet May Reduce the Risk of Death From Breast Cancer in Postmenopausal Women
Excluding skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. In 2019, the American Cancer Society estimates that about 268,600 new cases of breast cancer will be diagnosed in women, and about 41,760 women will die from their disease. ...
2019 ASCO: Lenalidomide May Reduce the Risk of Smoldering Multiple Myeloma Progressing to Active Disease
A phase III randomized trial (E3A06) by Lonial et al testing the effect of single-agent lenalidomide vs observation in patients with intermediate- or high-risk smoldering multiple myeloma has found that lenalidomide significantly reduces the risk of smoldering multiple myeloma progressing to active ...
FDA Approves Avelumab/Axitinib Combination for Advanced Renal Cell Carcinoma
On May 14, the U.S. Food and Drug Administration (FDA) approved avelumab (Bavencio) in combination with axitinib (Inlyta) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first FDA approval for an anti–programmed cell death ligand 1 (PD-L1)...
Tumor Mutational Burden as a Marker of Response to Immunotherapy in MSI-High Metastatic Colorectal Cancer
Foundational research recently published by Schrock et al in Annals of Oncology may help patients with microsatellite instability (MSI)-high metastatic colorectal cancer decide whether to choose immunotherapy or chemotherapy as their first treatment option. “Immunotherapy is the new,...
AUA Releases New Clinical Guideline for Diagnosis and Treatment of Early-Stage Testicular Cancer
Recently, the American Urological Association (AUA) released a new clinical guideline on the diagnosis and treatment of early-stage testicular cancer. Testicular cancer is the most common cancer among men ages 20 to 40. Although it is a less common form of cancer, about 9,600 American men...
Alcohol Intake and Risk of Lethal Prostate Cancer
As reported by Downer et al in the Journal of Clinical Oncology, findings from the Health Professionals Follow-up Study indicate that moderate alcohol consumption is safe for patients with prostate cancer. Study Details The prospective cohort study used data from the Health Professionals...
Addition of Tucidinostat to Exemestane in Advanced Hormone Receptor–Positive Breast Cancer
In the Chinese phase III ACE trial reported in The Lancet Oncology, Jiang et al found that the addition of the oral histone deacetylase inhibitor tucidinostat to exemestane improved progression-free survival in postmenopausal women with advanced hormone receptor (HR)-positive breast cancer whose...
Lifetime Risk of Brain Metastases in Elderly Survivors of Breast, Lung, and Skin Cancers
Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life, and may require extra surveillance in the years following initial cancer treatment, according to results of a study published by Ascha et al in Cancer Epidemiology, Biomarkers, &...
Study Finds New Candidate Susceptibility Genes for High-Grade Serous Ovarian Cancer
A team of researchers have identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer. The findings, published by Gusev et al in Nature Genetics, may help identify women who are at highest risk of developing ovarian cancer and pave the way...
HPV DNA and Outcomes After Primary Treatment for Oral and Oropharyngeal Squamous Cell Carcinomas
In a two-institution study reported in JAMA Oncology, Fakhry et al found that persistent detection of tumor-type human papillomavirus (HPV) DNA after primary treatment for oral and oropharyngeal squamous cell carcinomas was associated with poorer outcomes. Study Details The prospective study...
Sentinel Lymph Node Biopsy With or Without Use of Preoperative Lymphoscintigraphy in Early Breast Cancer
In a German/Swiss phase III trial (SenSzi [GBG80]) reported in the Journal of Clinical Oncology, Kuemmel et al found that preoperative lymphoscintigraphy was not associated with an increased number of histologically detected sentinel lymph nodes with sentinel lymph node biopsy in women with early...
Axitinib Plus Pembrolizumab in Advanced Sarcomas
In a phase II trial reported in The Lancet Oncology, Wilky et al found evidence of activity of axitinib plus pembrolizumab in advanced sarcomas, including alveolar soft-part sarcoma. Study Details The study involved 33 patients with advanced or metastatic sarcomas, including alveolar soft-part...
ARRS 2019: Percutaneous Liver Ablation Intervention vs Surgery for Hepatocellular Carcinoma
Compared to surgery, percutaneous liver ablation interventions in patients with hepatocellular carcinoma were associated with lower in-hospital mortality, length of hospital stay, and hospitalization costs, according to a study presented by Sodagari et al at the American Roentgen Ray Society...
ARRS 2019: Arterial-Phase Hyperenhancement for Hepatocellular Carcinoma Treated With SBRT
Although arterial-phase hyperenhancement is a key feature of untreated or recurrent hepatocellular carcinoma, standard response assessment such as modified Response Evaluation Criteria in Solid Tumors (mRECIST) should be used with caution, particularly in the early phases after stereotactic body...
ARRS 2019: Short-Interval Follow-up MRI in Identifying Early-Stage Breast Cancer
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast cancer and avoid unnecessary biopsies, according to a study presented by Lamb et al at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting (Abstract 2367). Utilization of ...
Ultradeep Sequencing of Plasma Cell-Free DNA in Bladder Cancer
In a study reported in the Journal of Clinical Oncology, Christensen et al found that identification of circulating tumor DNA (ctDNA) by ultradeep sequencing of plasma cell-free DNA was highly prognostic for outcome in bladder cancer and permitted early detection of relapse. The study...
Addition of Decitabine to Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
In a single-center phase II trial reported in the Journal of Clinical Oncology, Nie et al found a higher complete response rate with the addition of low-dose decitabine to the programmed cell death protein 1 (PD-1) inhibitor camrelizumab in anti–PD-1 treatment–naive patients with...
FDA Approves Ramucirumab for Hepatocellular Carcinoma
On May 10, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza) as a single agent for hepatocellular carcinoma in patients who have an alpha-fetoprotein (AFP) level ≥ 400 ng/mL and have been previously treated with sorafenib. REACH-2 Trial Approval was based on the...
For Your Patients: New ASCO Answers Fact Sheet on Immunotherapy Side Effects
IMMUNOTHERAPY IS changing the way that cancer is being treated, but the understanding of the side effects of these treatments is still a developing field. The ASCO Answers “Side Effects of Immunotherapy” fact sheet helps patients learn about which side effects may arise from treatment with...
Third Brazilian Practice Achieves QOPI® Certification
ACREDITAR ONCOLOGY has become the 3rd practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC, and the 10th practice internationally to receive this accreditation. The practice, located in Brasília’s Federal District,...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
NOT EVERY ONCOLOGIST grows up dreaming of becoming a doctor. In the Your Stories podcast episode “The Forest Ranger in a White Coat,” once-reluctant physician Stuart Spigel, MD, shares how becoming a patient changed his approach to practicing medicine with his son and fellow oncologist David...
ASCO Launches FY 2020 Advocacy Campaign for Federally Funded Cancer Research
ASCO HAS KICKED OFF its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH)—a $2.5 billion increase from FY 2019— and $6.5 billion to the National Cancer...
Enhance Your 2019 ASCO Annual Meeting Experience at Podcast Listening Station
THE ASCO ANNUAL Meeting is 5 bustling days of cutting-edge research presentations, educational sessions, and networking events. To enhance conference takeaways and connect attendees more closely with content from the 2019 Annual Meeting, ASCO will host a podcast listening station onsite at...
Conquer Cancer and Swim Across America: Making Waves to Fight Cancer
ASCO and ASCO’s Conquer Cancer Foundation have a new partner in supporting innovative cancer research. For over 30 years, Swim Across America (SAA) has been hosting charity swims, with the proceeds being granted to fund high-risk, high-reward cancer research. SAA is among the newest organizations...
CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain
ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) recently acknowledged receipt of a key clarification1 from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. The clarification...
Study Finds Immune Enrichment Improves Outcomes in Pancreatic Cancer With Activated but Not Normal Stroma
ALTHOUGH IMMUNOTHERAPIES have had limited success in pancreatic cancer to date, findings from a molecular analysis of the tumor microenvironment suggest that certain subtypes may be more responsive to treatment. According to data presented at the 2019 Society of Surgical Oncology Annual Cancer...
FDA Advances Policy Changes to Modernize Mammography Services
ON MARCH 27, 2019, the U.S. Food and Drug Administration (FDA) announced important new steps to modernize breast cancer screening and help empower patients with more information when they are considering important decisions regarding their breast health care. For the first time in more than 20...
Postprogression Treatment of Estrogen Receptor–Positive Breast Cancer: Future Approaches
AT THE 2019 Miami Breast Cancer Conference, William J. Gradishar, MD, FASCO, presented a vision of the future in the treatment of advanced hormone receptor–positive breast cancer.1 The refinement of disease subsets, the development of agents targeting the PI3K/AKT/mTOR pathway, the use of novel...
Emil J Freireich, MD, FAACR, Honored With AACR Award for Lifetime Achievement in Cancer Research
THE AMERICAN Association for Cancer Research (AACR) recognized Emil J Freireich, MD, FAACR, with the 2019 AACR Award for Lifetime Achievement in Cancer Research at the opening ceremony of this year’s AACR Annual Meeting. Dr. Freireich was honored for his work in establishing combination...
Pembrolizumab as Third-Line Option for Extensive-Stage Small Cell Lung Cancer
USE OF the anti–programmed cell death protein 1 (anti–PD-1) checkpoint inhibitor pembrolizumab after two or more prior lines of therapy led to responses in patients with advanced small cell lung cancer (SCLC) in a pooled analysis of two clinical trials: phase Ib KEYNOTE-028 and phase II...
AACR Study Presentations Include New Data in Breast and Prostate Cancers, Sarcoma, and High-Risk Individuals
THE 2019 American Association for Cancer Research (AACR) Annual Meeting was held March 29 to April 3 in Atlanta. In addition to our regular coverage of news stories from the meeting, here are some brief highlights of additional noteworthy studies. Stage IV HER2-Positive Breast Cancer: Surgery or No ...
Expert Point of View: Louis M. Weiner, MD, and Thomas Habermann, MD
“THIS REPRESENTS the fruits of years of research. Umbralisib is a more potent and selective PI3K inhibitor targeted to the delta isoform. This provides a more precise target for drugs that block that protein, and it more effectively disables signaling. The B cell is central to the survival of...
Umbralisib: Potential Option for Relapsed or Refractory Marginal Zone Lymphoma
UMBRALISIB—an investigational PI3K-delta inhibitor—produced impressive results as monotherapy in patients with relapsed or refractory marginal zone lymphoma, according to an interim analysis of the phase II UNITY-NHL trial presented at the 2019 American Association for Cancer Research (AACR) Annual ...
Expert Point of View: Namrata Vijayvergia, MD
NAMRATA VIJAYVERGIA, MD, of Fox Chase Cancer Center, Philadelphia, commented on this study. “This is an important study because it is done in a rare tumor type; not a lot of clinical trials are conducted in this disease. Recently, three other studies of single-agent therapy with checkpoint...
Dual-Immunotherapy Approach Shows Efficacy in High-Grade Neuroendocrine Tumors
COMBINING TWO established immunotherapy agents achieved tumor shrinkage in rare, aggressive, extrapancreatic high-grade neuroendocrine tumors, according to the results of SWOG S1609, a phase II clinical basket trial also known as DART (Dual Anti– CLTA-4 and Anti–PD-1 Blockade in Rare Tumors). The...
Expert Point of View: Roy S. Herbst, MD, PhD
FORMAL STUDY discussant, Roy S. Herbst, MD, PhD, Chief of Medical Oncology at the Yale Cancer Center, New Haven, Connecticut, stated that the findings of the TATTON analyses are “compelling,” and the combination of osimertinib plus savolitinib can be considered a “win,” although randomized trials...
Osimertinib Plus Savolitinib in Advanced NSCLC Driven by MET Resistance
THE ADDITION of the MET inhibitor savolitinib to the EGFR inhibitor osimertinib led to activity in patients with MET-amplified, EGFR-mutated non–small lung cancer (NSCLC) with acquired resistance to previous therapies, according to interim results from two expansion cohorts of a phase Ib clinical...
Front-Line Therapy in Advanced Renal Cell Carcinoma: Developing a New Standard
THE FRONT-LINE systemic treatment landscape for metastatic renal cell carcinoma has undergone tremendous movement over the past several years. A better understanding of the current management paradigm for therapy-naive patients warrants a reflection of historic landmark clinical trials that have...
Harnessing the Power of Twitter for Clinical Trial Enrollment and Success
CLINICAL TRIALS are vital for advancing cancer care for our patients. Each trial represents an unanswered problem for which researchers are committed to solving. Designing, funding, recruiting, and completing a trial are tremendous undertakings for each researcher, physician, patient, and...
Neoadjuvant Immunotherapy Associated With Improved Outcomes in Patients With Locally Advanced Melanoma
ACCORDING TO DATA from a small prospective study presented at the 2019 Society of Surgical Oncology Annual Cancer Symposium,1 neoadjuvant immunotherapy significantly prolonged relapse-free survival vs adjuvant immunotherapy in patients with stage III or oligometastatic stage IV melanoma intended...
FDA Pipeline: Designations in Triple-Negative Breast Cancer, ctDNA Detection
This week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for CCR5-positive metastatic triple-negative breast cancer; granted Breakthrough Device designation to a test for the postsurgical detection and quantification of circulating tumor DNA (ctDNA);...
PRRT Shows Long-Term Effectiveness in Malignant Neuroendocrine Tumors
A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrated the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study was published by...
IMPACT Study, Aimed at Increasing Diversity Among Clinical Trial Participants, Launches
The University of Southern California (USC) Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities....
Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
In a phase I trial reported in The New England Journal of Medicine, Raje et al found that bb2121, a chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), was safe in heavily pretreated patients with relapsed or refractory multiple myeloma. Investigators reported ...
Oropharyngeal Cancer Trends in White Men
In a study reported in the Journal of Clinical Oncology, Tota et al found that there has been a reduction in the increase of oropharyngeal cancer among young white men, with a high number of cases projected among older white men in coming years. As stated by the investigators, “Human...
Link Between Skin Cancer Diagnosis and Health-Care Screening Practices
According to findings published by Drucker et al in JAMA Dermatology, patients undergoing health-care screening practices for skin cancer have a higher likelihood of being diagnosed—particularly for squamous cell and basal cell carcinomas—than those who do not. Researchers...
PD-1 Inhibitor–Associated Cutaneous Toxicity and Clinical Outcomes in Advanced Melanoma
In a research letter published in JAMA Oncology, Quach et al found that cutaneous toxicities related to anti–programmed cell death protein 1 (PD-1) treatment—specifically, vitiligo and rash—were associated with improved clinical outcomes in advanced melanoma. Study Details The...
AMA Commends Final CMS Rule for Requiring Pricing Information in TV Drug Ads
Today, Health and Human Services Secretary Alex Azar announced a final rule from the Centers for Medicare & Medicaid Services (CMS) that will require direct-to-consumer television advertisements for prescription pharmaceuticals covered by Medicare or Medicaid to include the list price—the ...
